Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

Sally Hopewell and John Christianson

Sally works within OCTRU as Professor of Clinical Trials and Evidence Synthesis. She is involved in leading the design and delivery of clinical trials within the OCTRU portfolio. She is also co-chief investigator on several NIHR funded trials for interventions for people with shoulder pain and impaired shoulder function. Her key areas of research expertise are in the design, conduct and transparent reporting of randomized trials and systematic reviews.  

On receiving the award, Sally said “I am honoured and proud to receive this award and title Professor as part of this year’s Recognition of Distinction exercise. 

To me, this award shows recognition of the importance of conducting high quality trial methodology research and how it can be used to inform the design, conduct and reporting of future clinical trials; such as those carried out by the Oxford Clinical Trials Research Unit (OCTRU) and Centre for Statistics in Medicine (CSM).  

I am very grateful of the invaluable support I have received during my academic career and also pleased to add to the increasing number of female Professors within the Medical Sciences Division. I hope to inspire and encourage others to pursue a career in trial methodology research.”   

John is Professor and CRUK Senior Research Fellow in the Oppermann GroupHis research investigates the fundamental mechanisms and effects of cellular stress on cancers and many other diseases. His work explores new strategies for cancer intervention to prevent the progression of the disease.

He said “It is a great privilege to become a full professor at the University of Oxford. I owe this achievement to the hard work and tenacity of my DPhil students and post-docs, who have breathed the life into our research that enables it to flourish. 

Similar stories

Dr Alex Clarke wins Emerging Leaders Prize for lupus research

Alex is one of three exceptional lupus researchers that have been announced as winners of the Medical Research Foundation’s sixth Emerging Leaders Prize.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.

World Osteoporosis Day 2022

A bone-healthy lifestyle is vital for strong bones and a mobile, fracture-free future. On World Osteoporosis Day, we are sharing advice from the International Osteoporosis Foundation (IOF), on putting your bone health first.